Chris Shibutani
Stock Analyst at Goldman Sachs
(2.69)
# 2,120
Out of 5,012 analysts
96
Total ratings
54%
Success rate
3.28%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $41.87 | +138.83% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $2.48 | +20.97% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $20.09 | -25.34% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $30.95 | +3.39% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $106.06 | +29.17% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $16.45 | +100.61% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $456.84 | -33.89% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $36.10 | +41.27% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $188.89 | -17.94% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $13.49 | -70.35% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $10.60 | +88.68% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $843.63 | -14.30% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $20.16 | +28.97% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $137.00 | +11.68% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $232.83 | -25.70% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $58.00 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $44.66 | +54.50% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $17.20 | -24.42% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $46.57 | -50.61% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $3.98 | +1,156.28% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $56.92 | -8.64% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.27 | +128.40% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $5.85 | +207.69% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $7.29 | +133.20% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.82 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.17 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.18 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $41.87
Upside: +138.83%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $2.48
Upside: +20.97%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $20.09
Upside: -25.34%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $30.95
Upside: +3.39%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $106.06
Upside: +29.17%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $16.45
Upside: +100.61%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $456.84
Upside: -33.89%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $36.10
Upside: +41.27%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $188.89
Upside: -17.94%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $13.49
Upside: -70.35%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $10.60
Upside: +88.68%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $843.63
Upside: -14.30%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $20.16
Upside: +28.97%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $137.00
Upside: +11.68%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $232.83
Upside: -25.70%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $58.00
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $44.66
Upside: +54.50%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $17.20
Upside: -24.42%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $46.57
Upside: -50.61%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $3.98
Upside: +1,156.28%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $56.92
Upside: -8.64%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.27
Upside: +128.40%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $5.85
Upside: +207.69%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $7.29
Upside: +133.20%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.82
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.17
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.18
Upside: -